The phase II trial (BYlieve), a multicenter open-label, non-comparative study, showed the efficacy of Alpelisib plus Fulvestrant in patients with PIK3CA-mutated HR +/HER2− BC also pre-treated with CDK4/6 inhibitors [73]. Here, PIK3CA is linked to breast cancer.